Drugs / AIV007
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05698329 | Mar 2023 → Mar 2025 overdue | diabetic macular edema, macular retinal edema, wet macular degeneration | AiViva BioPharma, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04422899 | Aug 2020 → Sep 2021 | wet macular degeneration | AiViva BioPharma, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07557121 | Jul 2026 → Jun 2027 expected | wet macular degeneration | AiViva BioPharma, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIV007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05698329 ↗ |
| Action | Inhibit | “AIV007 is a multiple kinase inhibitor” NCT04422899 ↗ |
| Route | Intravitreal | “AIV007 is a novel, thermoresponsive gel suspension for intravitreal administration” NCT04422899 ↗ |